Virttu: TNK Therapeutics Inc. to Acquire Scotland-Based Co. in $34.4M Deal
TNK Therapeutics Inc., a subsidiary of San Diego's Sorrento Therapeutics Inc., is acquiring Scotland-based Virttu Biologics in a stock deal worth up to $34.4 million.
Read full article »
CEO
Virttu is engaged in the discovery and development of oncolytic immunotherapy for the treatment of cancer.
Read more